OrbiMed’s Applied Therapeutics APLT Stock Holding History

OrbiMed’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,050,921	Closed	-$2.32M	–	127
2022 Q4	$2.32M	Sell	3,050,921 -1,199,079	-28%	-$948K	0.04%	101
2022 Q3	$3.95K	Hold	4,250,000	–	–	0.07%	108
2022 Q2	$4.03K	Buy	+4,250,000	New	+$6.96M	0.07%	117
2022 Q1	–	Sell	-2,313,681	Closed	-$20.7M	–	145
2021 Q4	$20.7M	Buy	2,313,681 +56,294	+2%	+$739K	0.27%	84
2021 Q3	$37.5M	Hold	2,257,387	–	–	0.41%	68
2021 Q2	$46.9M	Hold	2,257,387	–	–	0.47%	59
2021 Q1	$42.3M	Buy	2,257,387 +485,556	+27%	+$10.5M	0.4%	68
2020 Q4	$39M	Buy	1,771,831 +225,144	+15%	+$4.69M	0.34%	69
2020 Q3	$32.1M	Buy	1,546,687 +329,009	+27%	+$8.55M	0.4%	67
2020 Q2	$44M	Sell	1,217,678 -102,199	-8%	-$4.28M	0.62%	51
2020 Q1	$43.1M	Buy	1,319,877 +332,691	+34%	+$13.5M	0.73%	44
2019 Q4	$26.9M	Buy	+987,186	New	+$16.9M	0.38%	59

Other funds holding APLT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

OrbiMed's APLT Position: Q1 2023 in Review

OrbiMed sold out of Applied Therapeutics (APLT) in Q1 2023, closing a stake of 3,050,921 shares — an estimated $2.32M sold.

OrbiMed first reported a position in APLT in Q4 2019 and held it in 12 quarters. The position peaked at $46.9M in Q2 2021. 36 funds tracked by Wall St. Rank hold APLT as of Q1 2023.

OrbiMed reported no remaining Applied Therapeutics position as of Q1 2023 after selling out during the quarter.
OrbiMed sold 3,050,921 Applied Therapeutics shares in Q1 2023, an estimated $2.32M.
OrbiMed first reported a position in Applied Therapeutics in Q4 2019 and held it in 12 quarters.
OrbiMed's Applied Therapeutics position peaked at $46.9M in Q2 2021.
36 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2023.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.